Karyopharm Therapeutic and Menarini Group have received complete marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Nexpovio (selinexor) along with bortezomib (Velcade) and dexamethasone (SVd) to treat multiple myeloma in adult patients.
The combination of Nexpovio, once-weekly bortezomib, and low-dose dexamethasone has received approval to treat adult patients who have previously received a minimum of one therapy.
Go deeper with GlobalData
The latest regulatory approval extends the indication of Nexpovio in Great Britain from conditional marketing authorisation to full approval.
Karyopharm Therapeutic president and CEO Richard Paulson said: “Receiving full marketing authorisation from the MHRA marks another significant milestone for Nexpovio.
“We are thrilled to expand the positive impact of NEXPOVIO to people living with multiple myeloma across Great Britain and continue working to further broaden access to selinexor across the globe.”
See Also:
The regulatory decision is supported by findings from the Phase III BOSTON study, which was conducted in 402 relapsed or refractory multiple myeloma adult patients who had previously received one to three lines of therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe trial was designed to compare the safety, certain health-related life parameters quality, and efficacy of once-weekly SVd against twice-weekly bortezomib plus low-dose dexamethasone (Vd).
According to the findings, once-weekly SVd showed a statistically significant reduction in the disease progression or death risk compared to twice-a-week bortezomib and dexamethasone (Vd).
Menarini CEO Elcin Barker Ergun said: “We are pleased by the MHRA’s decision to expand the indication for Nexpovio in Great Britain, bringing this important medicine to more people living with myeloma who may benefit.
“We look forward to delivering Nexpovio to patients and physicians in Great Britain as quickly as possible.”
The company’s wholly owned subsidiary Stemline Therapeutics will handle all commercialisation activities of Nexpovio in the UK.
